{"id":"NCT03461406","sponsor":"Instituto Grifols, S.A.","briefTitle":"A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants","officialTitle":"A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-18","primaryCompletion":"2022-04-15","completion":"2022-05-20","firstPosted":"2018-03-12","resultsPosted":"2023-04-07","lastUpdate":"2023-04-14"},"enrollment":186,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Excessive Bleeding During Surgery"],"interventions":[{"type":"BIOLOGICAL","name":"Fibrin Sealant Grifols","otherNames":["FS Grifols"]},{"type":"BIOLOGICAL","name":"EVICEL","otherNames":[]}],"arms":[{"label":"Fibrin Sealant Grifols","type":"EXPERIMENTAL"},{"label":"EVICEL","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the study is to evaluate if FS Grifols is non-inferior to EVICELÂ® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).","primaryOutcome":{"measure":"Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)","timeFrame":"From start of treatment until 4 minutes after treatment start (Day 1)","effectByArm":[{"arm":"Fibrin Sealant Grifols","deltaMin":100,"sd":null},{"arm":"EVICEL","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States","Bulgaria","Canada","France","Germany","Hungary","Romania","Serbia","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":91},"commonTop":["Vomiting","Anaemia","Pyrexia","Nausea","Hypertension"]}}